tirzepatide and mcas A newly published case series reports that GLP-1 receptor agonists (like semaglutide tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or Episode 91 - Dr. Tania

Following injection, the peptides demonstrate: Subcutaneous absorption with median time to maximum concentration (tmax) of 12-24 hours for GLP1 and 24-72 hours for cagrilintide High albumin binding for both peptides (approximately 99% for GLP1), providing protection from enzymatic degradation No pharmacokinetic interaction with co-administration not affecting exposure or elimination of either peptide Steady-state achievement occurring after 4-5 weeks of once-weekly dosing for both components Predictable dose-proportional exposure with area under the curve increasing proportionally with dose Phase 1b studies confirmed that cagrilintide doses from 0.16 to 4.5 mg produced area under the curve values ranging from 926 to 24,271 nmol times h/L, while GLP1 2.4 mg consistently produced values of 12,757 to 15,305 nmol times h/L regardless of cagrilintide co-administration dose

Compounded GHK-Cu from licensed pharmacies ensures pharmaceutical-grade quality but increases costs by 20-40% compared to research suppliers

But it's becoming apparent that the medications, which include others in its class and mimic a naturally produced hormone called GLP-1, might offer additional benefits, dampening cravings for things other than food

TRT delivers bioidentical testosterone directly, which can restore levels quickly but doesnt address the root cause of low T if its related to excess body fat

Nasal drug administration: potential for targeted central nervous system delivery